Skip to Content
Contact DCTD
Show menu
Search this site
Last Updated: 05/23/2024

2024 American Society of Clinical Oncology Annual Meeting

Schedule of DCTD Presentations


DCTD-supported research will be presented at the ASCO Annual Meeting from June 1- June 3, 2024.

The following tables include presentations containing DCTD staff speakers and co-authors.

Oral Presentations

Date/Time Title ID
June 2
4:30 - 6:00 PM
Randomized phase II/III study of R-CHOP +/- venetoclax in previously untreated MYC/BCL2 double expressor diffuse large B cell lymphoma (DLBCL): Alliance A051701 External Link 7012

Poster Sessions

Date/Time Title/DCTD Presenter (If Applicable) ID
June 1
9:00 AM - 12:00 PM
Correlations between first cycle toxicity and overall survival in patients with rare cancers treated with immune checkpoint inhibitors (NCI/SWOG S1609) External Link 2655
A phase I study of ATR inhibitor BAY1895344 (elimusertib) plus topotecan (ETCTN 10402): Results of dose escalation External Link 3076
A phase I study of irinotecan combined with BAY1895344 (ATR inhibitor) in advanced solid tumors: Results of ETCTN 10402 dose escalation External Link 3077
Dabrafenib and trametinib in patients with tumors with BRAF V600E/k mutations: Updated results from NCI-MATCH arm H External Link 3110
A phase 1 study of the BET inhibitor ZEN003694 in combination with the MEK1/2 inhibitor binimetinib in solid tumors with RAS pathway alterations and triple-negative breast cancer (NCI number 10449) External Link TPS3182
Pilot study of CBX-12 pharmacodynamics in patients with advanced solid tumors External Link
Dr. Sarah Shin
June 1
1:30 PM - 4:30 PM
ETCTN 10366: A phase 1 study of DNA-PK inhibitor peposertib in combination with hypofractionated radiotherapy for the treatment of locally advanced pancreatic adenocarcinoma External Link 4168
Association between circulating tumor DNA (ctDNA) and recurrence-free survival (RFS) in patients (pts) with resected stage III melanoma: An exploratory analysis of SWOG S1404 External Link 9564
A prognostic model based on selected cell state and cellular community scores in patients with advanced melanoma treated with immune checkpoint inhibitors (Ecotype-ICI score) as a predictor of ICI immunotherapeutic benefits External Link 9568
Correlative results from NCI CTEP/ETCTN 10330: A phase 2 study of belinostat with SGI-110 (guadecitabine) or ASTX727 (decitabine/cedazuridine) for advanced conventional chondrosarcoma (cCS) External Link 11526
Safety and toxicity evaluation of the combination of selinexor with atezolizumab in patients with soft tissue sarcomas External Link
Dr. Jibran Ahmed
A phase II randomized control trial of triapine plus lutetium 177 DOTATATE versus lutetium 177 DOTATATE alone for well-differentiated somatostatin receptor-positive neuroendocrine tumors External Link TPS4202
June 2
9:00 AM - 12:00 PM
CTEP 10492, a phase 1/1b study of the AKT inhibitor ipatasertib with chemoradiation for locally advanced head and neck squamous cell carcinoma External Link TPS6127
June 3
9:00 AM - 12:00 PM
Molecular profiling of plasma from matched NCI-MATCH gynecological cancers External Link 5579

Staff Kiosk Schedule — Booth #12023

Date Time Presenter
June 1 1:00 - 3:00 PM Sharad Verma, Ph.D.
Developmental Therapeutics Program
June 2 11:00 - 1:00 PM Sharad Verma, Ph.D.
Developmental Therapeutics Program
June 3 11:00 - 1:00 PM Sharad Verma, Ph.D.
Developmental Therapeutics Program
3:00 - 5:00 PM Beverly Teicher, Ph.D.
Developmental Therapeutics Program